<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914744</url>
  </required_header>
  <id_info>
    <org_study_id>LMTG 13-03</org_study_id>
    <nct_id>NCT01914744</nct_id>
  </id_info>
  <brief_title>Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL</brief_title>
  <official_title>Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Virus Reactivation in Patients With Non-Hodgkin Lymphoma on CHOP/R-CHOP: a Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to prove the superiority of entecavir over lamivudine for preventing
      the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on
      CHOP/R-CHOP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In china, previous studies showed patients with non-Hodgkin lymphoma (NHL) are likely to have
      hepatitis B virus (HBV) infection. The risk of HBV reactivation is high when patients were
      treated with CHOP, especially in combination with rituximab. The aim of this study is to
      compare entecavir with lamivudine, 2 commonly used anti-virus agents, for preventing the risk
      of HBV reactivation in patients with NHL on CHOP/R-CHOP.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of HBV reactivation</measure>
    <time_frame>12 months</time_frame>
    <description>Defined by increased level of HBV DNA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of hepatitis and HBV reactivation-related hepatitis</measure>
    <time_frame>6 months</time_frame>
    <description>Defined by increased level of alanine transaminase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate and median time of treatment delay due to hepatitis</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by information of treatment delay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate and median time of HBV DNA level normalization</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by information of HBV DNA level normalization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of drug resistance of viral variants</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Hepatitis B Reactivation</condition>
  <arm_group>
    <arm_group_label>entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>entecavir 0.5 mg/day PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lamivudine 100 mg/day PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>entecavir 0.5 mg/day PO</description>
    <arm_group_label>entecavir</arm_group_label>
    <arm_group_label>lamivudine</arm_group_label>
    <other_name>baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>lamivudine 100 mg/day PO</description>
    <arm_group_label>entecavir</arm_group_label>
    <arm_group_label>lamivudine</arm_group_label>
    <other_name>epivir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated NHL suitable for CHOP/R-CHOP treatment

          -  Age range 18-80 years old

          -  HBsAg positive with high level of HBV DNA

          -  Eastern Cooperative Oncology Group performance status 0-2

          -  Life expectancy of more than 3 months

          -  Adequate organ function

        Exclusion Criteria:

          -  Primary or secondary central nervous system involvement

          -  With hepatitis C virus infection

          -  Previous serious cardiac disease

          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix

          -  Pregnant or lactating women

          -  Serious uncontrolled diseases and intercurrent infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ye Guo, MD</last_name>
    <phone>+86 21 64175590</phone>
    <phone_ext>8906</phone_ext>
    <email>pattrick_guo@msn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Guo, MD</last_name>
      <phone>+86 21 64175590</phone>
      <phone_ext>8906</phone_ext>
      <email>pattrick_guo@msn.com</email>
    </contact>
    <investigator>
      <last_name>Ye Guo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>July 31, 2013</last_update_submitted>
  <last_update_submitted_qc>July 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Ye Guo</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>HBV</keyword>
  <keyword>entecavir</keyword>
  <keyword>lamivudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

